6 articles

Compounded GLP-1s: the rules, and what is in the vial

Most of the GLP-1 market that grew up online was built on one federal permission, and that permission has closed. These articles cover what compounding is allowed to be, what changed and when, and the more practical question underneath it: what is in the vial you were sent, how it differs from the approved product, and who decided the concentration.

  1. Which GLP-1s Can Be Compounded? The FDA Shortage and Bulks-List Rules

    Both federal routes for compounding semaglutide and tirzepatide depended on FDA shortage status. Both shortages are closed, and FDA has proposed shutting the remaining route.

    7 min read · 3 citations
  2. Compounded Semaglutide and Tirzepatide Are Ending: What to Do Next

    The federal permission that made large-scale GLP-1 compounding lawful has closed. Three routes remain, one to avoid, and the questions to ask before you move.

    6 min read · 3 citations
  3. Do You Need a Prescription for Compounded Semaglutide?

    Yes — but 503A and 503B do not carry the same requirement, and the gap between them is where the no-prescription pitches live. What each route actually asks for.

    5 min read · 3 citations
  4. Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different

    Compounded semaglutide can contain the same molecule as Ozempic and Wegovy, but the formulation, the concentration, the dose ladder and the adverse-event record are not the same thing at all.

    9 min read · 6 citations
  5. What Is in a Compounded GLP-1 Vial: How to Read the Label

    An approved pen delivers a dose; a compounded vial delivers a concentration, and someone has to convert one into the other. This is how to read the label, not how to dose.

    9 min read · 8 citations
  6. Why Compounded Semaglutide Is Mixed With B12

    What is actually established about the B12 in compounded semaglutide, what is only claimed, and the questions to put to the pharmacy that mixed it.

    7 min read · 7 citations